Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.
For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
Brigham and Women's Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Robert Swor, Royal Oak, Michigan, United States
Harborview Medical Center, Seattle, Washington, United States
China Medical University, Shenyang, Liaoning, China
Seoul St. Mary's Hospital, Seoul, Korea, Republic of
Peradeniya Teaching Hospital, Peradeniya, Central Province, Sri Lanka
CHU Nancy/Brabois, Vandoeuvre-Les-Nancy, France
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
Department of minimal invasive gynecology Aleris-Hamlet Private Hospital, Søborg, Denmark
Radboud university medical center, Nijmegen, Netherlands
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.